Tusk Innovation ประกาศเปิดตัวผลิตภัณฑ์ใหม่ “แบบผสานรวม”

TUSK PRODUCT

TUSK PRODUCT ZEN

ลอนดอน, Nov. 25, 2022 (GLOBE NEWSWIRE) — Tusk Inc. Limited (www.tusklimited.com) บริษัทซึ่งเริ่มก่อตั้งขึ้นในปี 2012 เพื่อเป็นบริษัทจัดการเงินทุนในสหราชอาณาจักรและกัวลาลัมเปอร์ โดยมีสำนักงานอยู่ทั่วโลกและปัจจุบันเป็นหนึ่งในบริษัทชั้นนำด้านโซลูชันไฟฟ้าที่มุ่งเน้นการผลิตไฟฟ้าสำหรับผู้ใช้อุปกรณ์การขุดสกุลเงินดิจิทัล พลังงานแสงอาทิตย์ และอะแดปเตอร์นั้น ได้ประกาศเปิดตัวผลิตภัณฑ์ใหม่ที่เป็นการผสานรวมการทำงาน สายผลิตภัณฑ์นี้ส่วนใหญ่มีไว้ใช้เพื่อวัตถุประสงค์ทางไฟฟ้า สำหรับนักขุดบิตคอยน์ ผลิตภัณฑ์ดังกล่าวมาพร้อมกับแผงโซลาร์เซลล์เพื่อลดการใช้พลังงาน ดูผลิตภัณฑ์ที่นี่ https://tusklimited.com/products

ในฐานะที่เป็นหนึ่งในสุดยอดบริษัทโซลูชันไฟฟ้า Tusk Innovation ได้ประกาศส่วนลด 30% สำหรับชุดอุปกรณ์การขุดเหรียญที่ผสานรวมแผงโซลาร์เซลล์เข้ากับเครื่องขุดบิตคอยน์ เมื่อเร็วๆ นี้ Tusk Inc. ได้เปลี่ยนจากวัสดุโพลีคริสตัลไลน์ (Polycrystalline) ไปเป็นโฟโตวอลเทอิก (Photovoltaic) และได้ทดสอบประสิทธิภาพของการผสมผสานผลิตภัณฑ์พลังงานแสงอาทิตย์เข้ากับเครื่องขุดสกุลเงินดิจิทัล และได้พิสูจน์แล้วว่าการผสมผสานนี้ทำให้เกิดประสิทธิผลมากที่สุด ขณะนี้นักลงทุน Tusk Inc. สามารถขุดเหรียญของตนได้อย่างง่ายดายโดยไม่มีการหยุดชะงัก จึงมีความเสี่ยงน้อยกว่าและทำกำไรได้สูงสุด

นี่คือความพยายามที่จะลดปริมาณการใช้ไฟฟ้าขณะที่ลูกค้าขุดสกุลเงินดิจิทัล และ John Walls ประธานเจ้าหน้าที่บริหาร ได้เปิดเผยเรื่องนี้เมื่อสัปดาห์ที่แล้ว จากคำกล่าวของ Walls ที่ว่า “รายงานต่าง ๆ ที่เผยแพร่ไปทั่วนั้นทำให้เห็นได้ชัดว่า ปริมาณไฟฟ้าที่นักขุดเหรียญต้องใช้นั้นอาจมากเกินที่จะจัดการได้ ดังนั้นเราจึงจัดให้มีตัวเลือกที่สมเหตุสมผล”

กำไรจากการขุดเหรียญ
แม้ว่าการทำฟาร์มขุดสกุลเงินดิจิทัลจะเป็นสิ่งที่น่าชื่นชมและทำกำไรได้สูงสำหรับหลายคน แต่ก็เป็นที่ทราบกันแพร่หลายในเรื่องการเก็งกำไรว่า นักขุดเหล่านั้นอาจมีค่าใช้จ่ายจำนวนมาก โดยเฉพาะอย่างยิ่งในแง่ของการใช้ไฟฟ้า การให้บริการแผงโซลาร์เซลล์ ซึ่งไม่มีส่วนเชื่อมโยงกับค่าไฟฟ้าของคุณและอุปกรณ์การขุดบิตคอยน์ที่สามารถทำงานโดยขุดสองเหรียญพร้อมกันได้นั้น ทำให้ Tusk Inc. สร้างโซลูชันที่ใช้งานได้ยาวนาน คุณสามารถขุดเหรียญได้อย่างง่ายดายและไม่ต้องกังวลเกี่ยวกับความผันผวนของตลาด พร้อมกับไม่ต้องสนใจการใช้พลังงานอีกด้วย

Tusk Inc. ได้สร้างความแตกต่างจากผู้ให้บริการรายอื่น โดยทำให้ลูกค้าได้รับบริการพัฒนากระเป๋าเงินคริปโตและได้รับหน่วยประมวลผลกราฟิกจากบริษัท ซึ่งมีสำนักงานต่าง ๆ อยู่ในสามทวีป บริษัทแห่งนี้ยังมีประสบการณ์มากมายในด้านการพัฒนาบล็อกเชน (Blockchain) และโซลูชันการขุดบิตคอยน์นอกเหนือจากด้านอื่น ๆ อีกด้วย

เกี่ยวกับ Tusk
Tusk Inc. ก่อตั้งขึ้นในปี 2012 โดยทีมผู้เชี่ยวชาญด้านการจัดการ แล้วต่อมาก็ได้ทีมผู้เชี่ยวชาญด้านเทคโนโลยีมาร่วมงานด้วย และขณะนี้ก็ถือเป็นหนึ่งในผู้ให้บริการโซลูชันไฟฟ้าชั้นนำ ผู้นำรายนี้ยังภาคภูมิใจในความสามารถในการจัดการความเสี่ยงได้อย่างมีประสิทธิผล เนื่องจากอยู่ในธุรกิจด้านการจัดการความเสี่ยงมาเป็นเวลานานกว่าทศวรรษแล้ว และจากความก้าวหน้าหลายอย่างในเทคโนโลยี พวกเขาจึงได้รวมกิจการร่วมทุนที่มีความเสี่ยงน้อยกว่าเข้ากับระบบการจัดการความเสี่ยง ซึ่งหนึ่งในนั้นก็คือการขุดสกุลเงินดิจิทัลโดยใช้วัสดุโฟโตวอลเทอิก

John Walls
ผู้จัดการฝ่ายประชาสัมพันธ์
john@tusklimited.com
(+44)7451214344

รูปภาพประกอบของการแถลงนี้สามารถรับชมได้ที่ https://www.globenewswire.com/NewsRoom/AttachmentNg/3b9f1b17-0a1a-4dce-bab8-8ffb601ccfac

GlobeNewswire Distribution ID 1000768791

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups.

LONDON, Nov. 24, 2022 (GLOBE NEWSWIRE) — In 2021, the global business jet market was USD 25.87bn and is expected to reach USD 38.34bn by 2029, growing at a CAGR of 4.06 %. Business jets flew 3.3 million flights worldwide in 2021, the most on record for a single year and 7 % more than the previous high point in 2019. Private jet statistics show a global fleet of 21,929 registered aircraft.

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups.

To expand KlasJet’s products portfolio, an EU-based corporate charter and ACMI services provider is adding Boeing BBJ2, MSN 32971 jet to its fleet. The aircraft is set to begin operations in mid-April 2023 and will be based in Dubai. The general sales agent for this aircraft will be Chapman Freeborn UAE Dubai office.

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups.

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups. “While our other 56-68 seats VIP Boeing 737 uniquely designed jets are great for larger groups, such as sports teams, business and political delegations, the B737 BBJ2 will serve as an amazing choice for affluent families, government representatives, presidents, royal families, important business delegations. Currently, the aircraft is at Avia Solutions Group completion centre JetMS Completion, where the interior of the jet will be fully renewed,” explains Rita Domkute, CEO of KlasJet.

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups.

 

Corporate business jet charter services are in great demand all over the world, as big groups can travel enjoying all the perks of business aviation: flexible flight time, luxury service on board, special seats and price per seat similar to business class seats at regular airline companies. “We plan that the newly added B737 BBJ2 will allow us to strengthen our positions in the rapidly growing Middle East market as the jet is a perfect option for high-ranking individuals who are living in or visiting the region on regular basis,” she shares.

The 23-seat aircraft is a truly exquisite project, with a spacious lounge area, an on-board bedroom and a shower. “The jet is designed to meet even the most sophisticated needs of our clients. It is planned with convenience and comfort of passengers in mind, the design is created using high-quality materials,” KlasJet’s CEO shares.

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups.

Earlier this year, the airline added passenger ACMI services list, adding to its parent company Avia Solutions Group’s ever-growing line-up of capacity providers.

If you would like more information or would like to schedule an interview with one of our KlasJet representatives, please contact Vilma Vaitiekunaite at vilma.vaitiekunaite@aviasg.com or +37061112789

About KlasJet 
KlasJet is an exlusive private and corporate jet charter company, renowned as a leader in the provision of bespoke group flights worldwide. Operating a fleet of uniquely designed jets based in Vilnius, Lithuania, as well as airports across Western and Eastern Europe, Africa, and the Middle East, KlasJet provides comfort, safety, and attention to detail from the ground up.

KlasJet adds Boeing 737 BBJ2 to its exclusive fleet

The Boeing 737 BBJ2 is a splendid addition to KlasJet’s exclusive private aircraft fleet as it is set to cater to the specific needs of high-ranking clients travelling in smaller groups.

KlasJet operates 7 corporate and BBJ Boeing 737 from 23 to 68 seats. Also offers ACMI lease services to airlines and tour operators around the world who face challenges with flight schedules, expansion plans, and the supply of backup aircraft. The company’s fleet available for ACMI lease services comprises 6 units of Boeing 737-800 — each with a capacity for 189 passengers.

KlasJet is a family member of Avia Solutions Group, leaders in end-to-end capacity solutions for passenger and cargo airlines worldwide. Its vast portfolio of services to clients includes ACMI, charter and cargo aviation, aircraft leasing and trading, MRO services, business aviation and VIP airline procurement, pilot and crew training, recruitment services, together with multiple complementary services spanning a wide range of associated operations. The Group manages over 100 offices and production facilities globally.

For more information, please visit: www.klasjet.aero and www.aviasg.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/ce2e4a06-4419-49c1-ba90-28dbffcb8dc8

https://www.globenewswire.com/NewsRoom/AttachmentNg/5b1ba671-7e18-4a06-accd-41f4e6ca73f6

https://www.globenewswire.com/NewsRoom/AttachmentNg/ea7cb8e9-3448-413a-954b-d25d02a70909

https://www.globenewswire.com/NewsRoom/AttachmentNg/4cef370a-1de1-4531-a17d-46b92282ef95

https://www.globenewswire.com/NewsRoom/AttachmentNg/67654115-fab4-422c-afd3-42548cabab14

https://www.globenewswire.com/NewsRoom/AttachmentNg/1a69f9ae-5ade-4675-9940-6d6e6bec2414

GlobeNewswire Distribution ID 1000768752

Intergalactic Social Media Launches the Galactix Zone Project

The first dynamic NFT game project will leverage dNFT technology to make strides in the worlds of blockchain and gaming.

Featured Image for Intergalactic Social Media, LLC

Featured Image for Intergalactic Social Media, LLC

RICHMOND, Va., Nov. 24, 2022 (GLOBE NEWSWIRE) — Intergalactic Social Media, a collective of crypto advisors and developers spearheaded by founders John Nguyen and Phea Ram, has officially launched its first NFT project, the Galactix Zone. The project, which has now been in development for over two years, is a community-focused effort utilizing a unique Non-Fungible Token (NFT) known as a Dynamic Non-Fungible Token (dNFT). Through its innovative design and model, Intergalactic Social Media aims to break through the mold by redefining NFTs and gaming itself.

After observing several NFT projects, Nguyen and Ram concluded that there was substantial potential for future opportunities and innovations within the space. Over time, they grew increasingly aware of the concerns surrounding the NFT space, including projects that seemed to promote static pixels in an attempt to merely ride a “hype train” and generate quick capital. Other projects went one step further and promised assets to investors just to completely fail to deliver on any of their previous promises.

Galactix Zone, also known as Galactix Zone Kalpa Avian or GKA, will set itself apart through innovations made possible by dNFT technology. Through dNFT, unique properties can be added or removed through the minting process. This innovation is merely scratching the surface of what is to come; GKA is scheduled to be just the first of several projects planning to be released in the ecosystem.

Unlike other projects that promote static NFT images, the Galactix Zone will feature dNFT assets that exist as living, breathing entities with synergistic integration and utility. This unique model gives our project the flexibility to truly innovate in the NFT space.

The implementation of the Galactix Zone project is currently pending internal review, with a detailed release soon to come. The Certik Audit and Certik KYC began on Oct. 31. The Galactix Zone team received a KYC Silver Verified rating on 11/21/2022 and a GEO RISK of a Tier 1 rating – The core team is in a country with the best ratings for international judicial cooperation, criminal justice, anti-money laundering, and corruption. Contextual data suggests the maximum level of geographical accountability, maximizing risk reduction and mitigation. A Certik (Certik.com) audit is an industry-leading security audit for web3 projects. This type of audit assesses smart contracts and blockchain code to address security concerns and identify vulnerabilities. A CertiK Know Your Customer (KYC) verification check is designed to put project teams through a rigorous vetting process while maintaining the highest standards of data protection.

Through these audits and verification checks, the Intergalactic Social Media team hopes to instill a strong sense of trust and transparency within the greater Galactix Zone community.

“Trust and transparency are fundamental principles for our project,” said Nguyen, who serves as the company’s CEO. “These processes will help ensure our community of who we are, what intentions we have currently, and what our future goals for the project will be. Ensuring trust and security is our top priority.”

The Intergalactic Social Media team plans to set aside one percent of its total token supply to be given to charity when the price hits $0.79. The time it will take for the token to reach that price will be determined by the level of pure synergetic teamwork between the developers and the community working together.

“We like to say that ‘FITS’ is in our DNA. FITS stands for fun, innovation, technology, and sustainability,” said Phea, who serves as CTO of Intergalactic Social Media.

“John and I were so captivated by the idea of decentralization when we first began reading about it. It can be so beneficial to all and used as a force for good. With that being said, we gave many of the early projects the benefit of the doubt, only to be burned by bad actors within the industry. We are determined to be different. Giving back to our community is a major focus of ours. We go as far as to say that it is in our tokenomics DNA.”

To learn more about the Galactix Zone, check out the team’s official project announcement video.

About Intergalactic Social Media, LLC

Intergalactic Social Media, LLC is the developer of the Galactix Zone project. Now in development for over two years, the project was initially founded by crypto investors John Nguyen, who serves as the CEO of Intergalactic Social Media, and Phea Ram, who serves as CTO.

In conjunction with a large team of advisors and developers, Nguyen and Ram have worked to bring Galactix Zone, the community-based game focused on giving back to society, to life.

https://discord.gg/2UqSqFJtbA

https://github.com/GalactixZone

https://www.tiktok.com/@galactixzone.io

https://twitter.com/GalactixZone

https://www.youtube.com/@galactixzone

https://www.instagram.com/galactixzone.io

https://www.facebook.com/galactixzone.io

https://www.linkedin.com/company/galactix-zone

Contact Information:
Phea Ram
CTO
marketing@galactixzone.io

Related Files

Galactix Zone Tokenomics 11-23-22.pdf

Related Images

Image 1

This content was issued through the press release distribution service at Newswire.com.

Attachment

GlobeNewswire Distribution ID 8702894

Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency

— 2nd MAA submission in Europe reflects toripalimab’s steady yet speedy progress towards global commercialization

SHANGHAI, China, Nov. 24, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company has submitted a marketing authorization application (“MAA”) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA”) for toripalimab. The indications requested in the MAA are: 1) Toripalimab, in combination with cisplatin and gemcitabine, for the first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma (“NPC”) and 2)Toripalimab, in combination with paclitaxel and cisplatin, for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (“ESCC”). Junshi Biosciences also submitted a MAA to the European Medicines Agency (“EMA”) for toripalimab for the same indications in mid-November.

“Within a single month, we were able to submit marketing authorization applications for toripalimab to two major European regulatory agencies,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi/TopAlliance Biosciences. “This is emblematic of our determination and corporate efficiency in bringing innovative drugs to patients worldwide. In the coming days, we will work closely with the MHRA to promote the clinical development and application of emerging therapies in the UK.”

The MAA submission for NPC and ESCC is based on the results from JUPITER-02 (an international randomized, placebo-controlled, double-blinded Phase III trial, NCT03581786) and JUPITER-06 (a randomized, placebo-controlled, double-blinded, multi-center Phase III trial, NCT03829969).

The JUPITER-02 results were first presented in the plenary session of the American Society of Clinical Oncology (“ASCO”) 2021 annual meeting (#LBA2) and subsequently published in detail as the cover article of the September 2021 issue of Nature Medicine. According to its final progression-free survival (PFS) analysis, the toripalimab plus chemotherapy arm had a significantly longer PFS than the placebo plus chemotherapy arm as assessed by a blinded independent radiology committee (BIRC) with median PFS of 21.4 vs. 8.2 months, hazard ratio (HR)=0.52 (95% CI: 0.37-0.73), two-sided p<0.0001.

In 2021, two indications for the treatment of NPC were approved by the China National Medical Products Administration (“NMPA”), thereby making toripalimab the world’s first immune checkpoint inhibitor approved for the treatment of NPC. In the the United States, the NPC indications of toripalimab have been granted 2 Breathrough Therapy Designations and 1 Orphan Drug Designation by the Food and Drug Administration (“FDA”), while the Biologics License Application (“BLA”) for toripalimab for the treatment of NPC is under review. If approved, toripalimab will be the first and only drug approved for the treatment of NPC in the U.S. In Europe, toripalimab was designated as an orphan medicinal product by the European Commission (“EC”) for the treatment of NPC.

The JUPITER-06 results were first presented in a mini-oral session during the 2021 European Society for Medical Oncology (“ESMO”) Congress and later published in Cancer Cell with an editorial preview. The overall survival (OS) and PFS were significantly better in the toripalimab plus chemotherapy arm than in the placebo plus chemotherapy arm, with a median OS of 17 vs. 11 months (HR=0.58, 95% CI: 0.43-0.78, P=0.0004) and PFS HR=0.58 (95% CI: 0.46-0.74), p<0.0001.

In May 2022, the supplemental new drug application (“sNDA”) for toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic ESCC was approved by the NMPA in China. Additionally, US FDA has also granted an orphan drug designation to toripalimab for the treatment of patients with ESCC.

About Nasopharyngeal Carcinoma
NPC is a malignant tumor that occurs in the nasopharyngeal mucosal epithelium and is one of the most common head and neck cancers in China. According to the World Health Organization, the number of newly diagnosed NPC cases in 2020 has exceeded 130,000 worldwide. Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with chemotherapy and radiotherapy. In the United States and Europe, there are presently no drugs approved for the treatment of NPC, for which recommendations for initial treatment (gemcitabine and cisplatin) are based on randomized trials conducted in China.

About Esophageal Cancer
Esophageal cancer is one of the most common malignant tumors in alimentary tract. According to data released by GLOBOCAN 2020, 604,100 new esophageal cancer cases and 544,076 deaths due to esophageal cancer occurred globally. The incidence and death rates of esophageal cancer ranked seventh and sixth among all malignant tumors around the world. ESCC and esophageal adenocarcinoma are the two main histological subtypes of esophageal cancer. For patients with advanced ESCC, recently updated ESMO guidelines recommend a platinum-fluoropyrimidine doublet with a PD-1 blocking antibody for treatment of locally advanced or metastatic ESCC. Of note, the indications for those PD-1 inhibitors approved in Europe are restricted to a subset of patients with ESCC. Therefore, there is an urgent unmet need for new drugs and treatments to extend the survival of patients with ESCC, particularly those with low PD-1 tumor expression.

About Toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are six approved indications for toripalimab in China:

  1. unresectable or metastatic melanoma after failure of standard systemic therapy;
  2. recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic ESCC;
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”).

The first three indications have been included in the National Reimbursement Drug List (“NRDL”) (2021 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma and NPC.

In the United States, the FDA is reviewing the BLA resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic NPC and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. The FDA has set a PDUFA action date for December 23, 2022. The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (“SCLC”).

In Europe, toripalimab was also designated as an orphan medicinal product by the EU’s European Commission for the treatment of NPC. In November 2022, MAA was submitted to the EMA and MHRA for: 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8703015

Thai medical tourism sector is roaring back from Covid-19 pandemic, analysts say

With Covid-era travel restrictions now relaxed, Thailand is once again underlining its reputation in the medical field by drawing in visitors wanting to benefit from the country’s natural attractions while also taking care of their medical problems. But while visitors are returning, analysts predict the industry will not rebound significantly until 2023 when touristnumbers really pick up.

 

Moving in the right direction

 

An analysis report from Krungthai Compass, a research house under Krungthai Bank, said Thailand’s medical tourism sectoris recovering from setbacks caused by the impacts of Covid-19 and especially from the now-cancelled Thailand Pass scheme.

 

A surge in foreign tourists flooding into Thailand over the past few months has improved footfalls at private hospitals and given a promising outlook to the country’s medical tourism industry.

 

According to news reports, more than 3.1 million foreign tourists arrived the country in October, a rise of more than43% over September.

 

Krungthai analyst Sujitra Unno said in an article published online that private hospitals’ footfalls improved significantly between January and June 2022, contributing to the recovery of the medical tourism sector.

 

She cited a report that sees 24 SET-listed private hospital service providers enjoying revenue and profit growth in the first quarter of 2022 when compared to the same period of the previous year.

 

According to her, the hospitals’ total revenues increased 48.9% year-over-year (YoY) to over 125 billion baht in the first quarter of 2022 and their net profits grew by 173.8% YoY to over 24 billion baht. The growth was mainly attributed torevenues from Thai patients who sought medical treatment for Covid-19 infections.

 

The research center predicted the private hospital business will continue to expand by 19.8% YoY in 2023, which will help boost the country’s medical tourism business as well as total foreign patient revenue which, pre-Covid, accounted for about 30% of the total.

 

During Covid, private hospitals, particularly large hospital chains reliant on revenue from foreign patients, fell significantly. This is confirmed in a report by Kasikorn Research Center, which noted that the number of medical tourist arrivals declined by some 90% in 2021, with visitors from the Middle East, ASEAN countries and China making up the majority of those forced to delay hospital consultations. Krungthai Compass estimates that of the 8.9 million foreign tourists who have arrived in Thailand in 2022, a relatively high percentage were here to receive medical treatment.

 

“We expect that next year, many private hospitals in Thailand will see their patients from China, Russia, Japan and the Middle East coming back to receive treatment services,” Sujitra said.

An ideal destination for medical tourism

 

High-quality medical care, cost-effectiveness and lower cost of living that is great for long-stay patients make Thailand a preferred destination for many international patients. This is also backed by the government’s efforts in turning the country into a ‘world medical center’.

 

Thailand tops other countries in Asia in the number of hospitals which have been accredited by Joint Commission International (JCI), the top global standard for health care quality and patient safety. The country boasts 60 JCI-accredited medical sites nationwide, while India has 37, Japan 31, Malaysia 17 and Singapore 5, according to the JCI list as of December 2021.

 

The JCI accreditation has become a key stamp of approval for hospitals in developing countries seeking medical tourists.

 

According to the Krungthai report, medical services in Thailand help patients save 50-90% on medical expenses compared to what they would pay for similar services in the US. The majority of medical tourists come to the country to receive dental treatment, followed by plastic surgery and cosmetic treatment.

 

In addition, several cities in Thailand are top-rated tourist destinations with the highest healthcare scores in Southeast Asia on Numbeo’s Health Care Index 2022 Mid-year. Chiang Mai is at the top of the list, followed by Bangkok in third place and Pattaya in fourth.

 

The index was conducted based on a survey of website visitors on the overall quality of the health care system that included doctors, healthcare professionals, staff and medical treatment costs.

 

Chiang Mai leads other cities due to its popularity amongst foreigners, the lower cost of living, convenience, local culture and high-quality public health system at an affordable price.

 

Gearing up to become a center of wellness and medical services

 

With these factors, Thailand’s potential for growth in this lucrative market is strong.

 

According to Allied Market Research, the global medical tourism market achieved approximately US$104.68 billion in 2019 and it’s expected to reach US$273.72 billion by 2027. The research center estimates Thailand’s medical tourism market will hit US$24.4 billion (or around 760 billion baht) in 2027, compared to US$9.1 billion (or around 200 billion baht) in 2019. In 2019, Thailand gained 9% of market share in global medical tourism.

 

The Thai government has taken measures to invigorate the medical tourism industry in order to bring the country to the forefront as a top medical hub in wellness, medical services, products and academics.

 

In addition to relaxing restrictions, the government has used the country’s excellent performance in tackling Covid-19 to promote its medical tourism and health treatment to attract foreign visitors.

 

Following the success of the Phuket Sandbox programme, the country’s pilot scheme to lure foreign visitors, it said it will turn the city into a world-class medical center and develop a plaza in the city that is equipped with an international elderly care center, rehabilitation center, and a palliative care center.

 

Last year, the cabinet approved in principle a new visa scheme that allows foreigners who seek medical treatment to stay in the country for up to a year, without having to leave the country for visa renewals if the arrive on tourist visas.

 

Source: Thai Public Broadcasting Service

Thailand’s car sales for the first ten months jump 17%

Domestic car sales in Thailand, in the first ten months of 2022, were 698,305 vehicles, representing a 17.09% increase, compared to the same period last year, according to the Federation of Thai Industries (FTI).

 

1,496,591 motorcycles were sold, an increase of 13.68% over the same period last year.

 

800,672 completely-built cars, worth about 497 billion baht, were exported during the January-October period, an increase of 12.40% over the same period last year.

 

The export value of cars, accessories and spare parts for the same period is estimated at 727 billion baht, an increase of 9.6%.

 

In October alone, 64,618 cars were sold, which is in line with the economic recovery, driven by increased foreign arrivals and economic stimulus packages, according to the FTI.

 

1,534,754 cars were produced in the first ten months of this year, which is an increase of 12.36% compared to the same period last year.

 

Source: Thai Public Broadcasting Service

FPT Software Opens New Office in Thailand, Targeting the Country’s Top 30 IT Companies

BANGKOK, FPT Software, Vietnam’s leading IT solutions provider, has recently announced the opening of a new office in Bangkok, Thailand. This branch, targeting the top 30 IT companies in Thailand, assists FPT Software’s strategic move to expand its global footprint.

 

The inauguration was attended by the Ambassador of the S.R. of Vietnam to Thailand, H.E. Phan Chi Thanh, KBTG Chairman Voranuch Dejakaisaya, KBTG Vice Chairman Jarung Kiatsuphapong, Unilever IT SEA Regional Head Piyawan Triyanant, FPT Software’s CHRO Nguyen Tuan Minh, FPT Software’s SVP Nguyen Hoang Trung, FPT Greater Bay Indochina (FPT GBI – a subsidiary of FPT Software) CEO Levi Nguyen, and other distinguished guests.

 

Source: Nam News Network

FIFA threatens to pull plug on World Cup broadcast rights in Thailand

FIFA has threatened to suspend broadcast rights for World Cup 2022 football matches in Thailand after it was discovered that audiences in two neighbouring countries can view the Thai transmissions, even though the broadcast rights for their countries have not been purchased.

 

According to the Sports Authority of Thailand (SAT), FIFA has demanded that Thailand meets the encryption standards required, otherwise it may pull the plug.

 

After receiving the notification from FIFA, the SAT called an urgent meeting with the parties concerned, among them the National Broadcasting and Telecommunications Commission (NBTC) and digital TV operators, to consider FIFA’s demand.

 

An SAT official said that the meeting concluded that they could not meet FIFA’s encryption standard, because the transmission technology employed by service providers is not advanced enough and the customers’ set-top boxes are not compatible with the required technology.

 

The meeting did agree, however, that they would propose to FIFA a change to the transmission code which, they believe, would prevent audiences in other countries gaining access to broadcasts in Thailand.

 

Regarding the reallocation of broadcast rights for the 64 football matches, following complaints of unfair allocation in favour of True Corporation by digital TV operators, an SAT official said that True Corp has decided to relinquish the rights to 16 of the 32 matches for redistribution among digital TV operators.

 

It was agreed that all of them will be allocated equal rights to air three matches each, instead of just two.

 

True was originally allocated the rights to air 32 matches, because it contributed about 300 million baht to the fund to buy the rights from FIFA, on top of the 600 million baht contributed by NBTC, but the amount was still short of the 1.4 billion baht required.

 

More Thai companies subsequently made contributions, making it possible for the Thai audience to watch all the 64 matches.

 

Thai PBS, the public service broadcaster, has the right to air the match today (Thursday) between Switzerland and Cameroon at 5pm and the match between Portugal and Ghana at 11pm, then the match on December 1st between Canada and Morocco.

 

Source: Thai Public Broadcasting Service